三博脑科24年度净利润劲增34.24%至1.05亿元 拟10派1.48元

Core Insights - Sanbo Brain Science has demonstrated strong resilience in its operations, achieving significant growth in both revenue and profitability for the year 2024 [1][2] Financial Performance - For the year 2024, Sanbo Brain Science reported a revenue of 1.429 billion yuan, an increase of 8.84% compared to the previous year [1] - The net profit attributable to shareholders exceeded 100 million yuan, reaching 105 million yuan, which represents a year-on-year growth of 34.24% [1] - The net profit excluding non-recurring gains and losses was 94 million yuan, showing a slight increase of 0.77% year-on-year [1] - Core business segments showed stable growth, with medical service revenue at 1.091 billion yuan (up 8.47%) and pharmaceutical revenue at 323 million yuan (up 7.97%) [1] Shareholder Returns - The company announced a profit distribution plan for 2024, proposing a cash dividend of 1.48 yuan per 10 shares (including tax), totaling 30.0425 million yuan [1] Business Expansion - Sanbo Brain Science operates eight hospitals across key regions in China, including five specialized neurology hospitals and three general hospitals [2] - The company has established a competitive edge in treating complex conditions, talent development, and research translation, supported by a team of expert academicians [2] - Recent acquisitions, including a supply chain company and a significant stake in another firm, have enhanced business synergies and expanded the company's operational footprint [3] Future Outlook - The company anticipates continued growth into 2025, with a first-quarter revenue increase of 16.78% to 393.4738 million yuan and a net profit growth of 14.56% [3] - Plans to expand hospital operations and enhance information technology infrastructure are in place to improve operational efficiency and service delivery [3]